BACKGROUND: This study is the first to examine longitudinal posttreatment outcomes of a placebo-controlled trial of varenicline for alcohol use disorder (AUD) with comorbid cigarette smoking. METHODS:Participants were 131 adults (n = 39 female) seekingalcohol treatment in a randomized, double-blind, parallel group, placebo-controlled, 16-week multisite trial of varenicline combined with medical management (MM). Timeline follow-back assessments of alcohol and smoking behavior were conducted at the end of treatment (4 months), with follow-ups at 6, 9, and 12 months. Outcomes were percentage of heavy drinking days (PHDD), percent of participants with no heavy drinking days (NHDD), cotinine-confirmed prolonged smoking abstinence (PA), and good clinical outcome on either NHDD or PA. RESULTS: Treatment improvements were maintained posttreatment. For the sample overall, PHDD or NHDD did not differ significantly by treatment condition (ps > 0.13), but varenicline produced higher rates of PA versus placebo at 4, 9, and 12 months (p < 0.05). Significant differences were observed by sex: Males had higher rates of NHDD with varenicline (28.9%) versus placebo (6.4%) at the end of treatment (p = 0.004), and these effects were maintained at 12 months (varenicline: 40.0% vs. placebo: 19.2%, p = 0.03). Higher rates of PA were seen for varenicline in both males (8.9%) and females (21.1%) versus placebo (males/females: 0%) at the end of treatment (p = 0.05), and this effect was maintained at 12 months for females (varenicline: 21.1% vs. placebo, 0.0%, p = 0.05). CONCLUSIONS:Varenicline treatment combined with MM appears to have enduring benefits for patients with co-occurring AUD and cigarette smoking, and these effects may differ by sex.
RCT Entities:
BACKGROUND: This study is the first to examine longitudinal posttreatment outcomes of a placebo-controlled trial of varenicline for alcohol use disorder (AUD) with comorbid cigarette smoking. METHODS:Participants were 131 adults (n = 39 female) seeking alcohol treatment in a randomized, double-blind, parallel group, placebo-controlled, 16-week multisite trial of varenicline combined with medical management (MM). Timeline follow-back assessments of alcohol and smoking behavior were conducted at the end of treatment (4 months), with follow-ups at 6, 9, and 12 months. Outcomes were percentage of heavy drinking days (PHDD), percent of participants with no heavy drinking days (NHDD), cotinine-confirmed prolonged smoking abstinence (PA), and good clinical outcome on either NHDD or PA. RESULTS: Treatment improvements were maintained posttreatment. For the sample overall, PHDD or NHDD did not differ significantly by treatment condition (ps > 0.13), but varenicline produced higher rates of PA versus placebo at 4, 9, and 12 months (p < 0.05). Significant differences were observed by sex: Males had higher rates of NHDD with varenicline (28.9%) versus placebo (6.4%) at the end of treatment (p = 0.004), and these effects were maintained at 12 months (varenicline: 40.0% vs. placebo: 19.2%, p = 0.03). Higher rates of PA were seen for varenicline in both males (8.9%) and females (21.1%) versus placebo (males/females: 0%) at the end of treatment (p = 0.05), and this effect was maintained at 12 months for females (varenicline: 21.1% vs. placebo, 0.0%, p = 0.05). CONCLUSIONS:Varenicline treatment combined with MM appears to have enduring benefits for patients with co-occurring AUD and cigarette smoking, and these effects may differ by sex.
Authors: Christopher W Kahler; Ron Borland; Andrew Hyland; Sherry A McKee; Mary E Thompson; K Michael Cummings Journal: Drug Alcohol Depend Date: 2008-12-03 Impact factor: 4.492
Authors: Douglas E Jorenby; J Taylor Hays; Nancy A Rigotti; Salomon Azoulay; Eric J Watsky; Kathryn E Williams; Clare B Billing; Jason Gong; Karen R Reeves Journal: JAMA Date: 2006-07-05 Impact factor: 56.272
Authors: Lisa M Fucito; Aesoon Park; Suzy Bird Gulliver; Margaret E Mattson; Ralitza V Gueorguieva; Stephanie S O'Malley Journal: Biol Psychiatry Date: 2012-04-26 Impact factor: 13.382
Authors: Stephanie S O'Malley; Allen Zweben; Lisa M Fucito; Ran Wu; Mary E Piepmeier; David M Ockert; Krysten W Bold; Ismene Petrakis; Srinivas Muvvala; Peter Jatlow; Ralitza Gueorguieva Journal: JAMA Psychiatry Date: 2018-02-01 Impact factor: 21.596
Authors: A B Lowenfels; P Maisonneuve; G Cavallini; R W Ammann; P G Lankisch; J R Andersen; E P DiMagno; A Andrén-Sandberg; L Domellöf; V Di Francesco Journal: Am J Gastroenterol Date: 1994-09 Impact factor: 10.864
Authors: Sherry A McKee; Emily L R Harrison; Stephanie S O'Malley; Suchitra Krishnan-Sarin; Julia Shi; Jeanette M Tetrault; Marina R Picciotto; Ismene L Petrakis; Naralys Estevez; Erika Balchunas Journal: Biol Psychiatry Date: 2009-02-27 Impact factor: 13.382
Authors: Robert F Leeman; Sherry A McKee; Benjamin A Toll; Suchitra Krishnan-Sarin; Judith L Cooney; Robert W Makuch; Stephanie S O'Malley Journal: Nicotine Tob Res Date: 2008-12 Impact factor: 4.244
Authors: Cassie M Chandler; Sarah E Maggio; Hui Peng; Kimberly Nixon; Michael T Bardo Journal: Drug Alcohol Depend Date: 2020-04-25 Impact factor: 4.492
Authors: Milan D Valyear; Mandy R LeCocq; Alexa Brown; Franz R Villaruel; Diana Segal; Nadia Chaudhri Journal: Psychopharmacology (Berl) Date: 2022-10-20 Impact factor: 4.415
Authors: Hilary A Tindle; Matthew S Freiberg; Debbie M Cheng; Natalia Gnatienko; Elena Blokhina; Tatiana Yaroslavtseva; Sally Bendiks; Gregory Patts; Judith Hahn; Kaku So-Armah; Michael D Stein; Kendall Bryant; Dmitry Lioznov; Evgeny Krupitsky; Jeffrey H Samet Journal: JAMA Netw Open Date: 2022-08-01